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Abstract
Introduction: This study was undertaken to determine whether the anti-osteoarthritis drug pentosan polysulfate
(PPS) influenced mesenchymal precursor cell (MPC) proliferation and differentiation.
Methods: Human MPCs were maintained in monolayer, pellet or micromass cultures (MMC) for up to 10 days with
PPS at concentrations of 0 to 20 μg/ml. MPC viability and proliferation was assessed using the WST-1 assay and
3H-thymidine incorporation into DNA, while apoptosis was monitored by flow cytometry. Proteoglycan (PG)
biosynthesis was determined by
35SO4
2- incorporation and staining with Alcian blue. Proteoglycan and collagen
type I and collagen type II deposition in pellet cultures was also examined by Toluidine blue and
immunohistochemical staining, respectively. The production of hyaluronan (HA) by MPCs in MMC was assessed by
ELISA. The relative outcome of PPS, HA, heparin or dextran sulfate (DS) on PG synthesis was compared in 5-day
MMC. Gene expression of MPCs in 7-day and 10-day MMC was examined using real-time PCR. MPC differentiation
was investigated by co-culturing with PPS in osteogenic or adipogenic inductive culture media for 28 days.
Results: Significant MPC proliferation was evident by day 3 at PPS concentrations of 1 to 5 μg/ml (P < 0.01). In the
presence of 1 to 10 μg/ml PPS, a 38% reduction in IL-4/IFNg-induced MPC apoptosis was observed. In 5-day MMC,
130% stimulation of PG synthesis occurred at 2.5 μg/ml PPS (P < 0.0001), while 5.0 μg/ml PPS achieved maximal
stimulation in the 7-day and 10-day cultures (P < 0.05). HA and DS at ≥ 5 μg/ml inhibited PG synthesis (P < 0.05)
in 5-day MMC. Collagen type II deposition by MMC was significant at ≥ 0.5 μg/ml PPS (P < 0.001 to 0.05). In MPC-
PPS pellet cultures, more PG, collagen type II but less collagen type I was deposited than in controls. Real-time PCR
results were consistent with the protein data. At 5 and 10 μg/ml PPS, MPC osteogenic differentiation was
suppressed (P < 0.01).
Conclusions: This is the first study to demonstrate that PPS promotes MPC proliferation and chondrogenesis,
offering new strategies for cartilage regeneration and repair in osteoarthritic joints.
Introduction
Adult mesenchymal stem cells (MSCs) are an abundant
source of self-renewing, multipotent undifferentiated
cells that can be readily isolated from bone marrow, adi-
pose tissue, muscle and synovium, and can be expanded
in ex vivo culture [1,2]. The ability of these cells to dif-
ferentiate into bone, cartilage, adipose, tendon and other
cells of the mesenchymal lineage under appropriate sti-
muli offers the potential for the regeneration and repair
of the musculoskeletal system by their direct application
to sites of injury [3-5] or by their incorporation into
bioscaffolds and transplantation into the sites of the tis-
sue defect [3,6,7].
Stromal tissue in the bone marrow consists of a het-
erogeneous population of MSCs that occupy a perivas-
cular niche [8-10]. Recent studies, however, provide
evidence for the existence within this niche of smaller
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proliferative and multilineage differentiative capacity and
can be distinguished by their expression of certain cell
surface antigens [11,12]. These undifferentiated
mesenchymal precursor cells (MPCs) can be isolated
from bone marrow aspirates using magnetic activated
cell sorting in combination with antibodies that identify
STRO-1, VCAM-1 (CD106), STRO-3 (tissue nonspecific
alkaline phosphatase), STRO-4 (HSP-90b) and CD146
[11,12]. Using this approach, a homogeneous population
of quiescent MPCs can be obtained that lack the pheno-
typic characteristics of leukocytes and mature stromal
elements and exhibit extensive proliferative capacity
while retaining the ability to differentiate into bone, car-
tilage and adipose tissues. This technique of selecting
MPCs from bone marrow aspirates therefore provides a
purer population of uncommitted bone marrow MSCs
than can be obtained using traditional methods of isola-
tion that rely on ficol gradient centrifugation, followed
by plastic adherence in culture flasks [1,2]. Subcuta-
neous implantation of STRO-1
+,S T R O - 3
+,S T R O - 4
+,
CD106
+ and CD146
+ MPCs together with an osteoin-
ductive hydroxy apatite/tricalcium phosphate carrier
into NOD/SCID mice resulted in the successful deposi-
tion of bone at the site of implantation [11-13].
Parallel experiments designed to generate cartilage in
vivo using the same model, however, necessitated subcu-
taneous implantation of MPCs combined with trans-
forming growth factor (TGF)-b3 within fibrin glue (A.C.
W. Zannettino and S. Gronthos, unpublished observa-
tions). Even though the TGF-b/bone morphogenetic
protein (BMP) superfamily of growth factors are the
most extensively used inducers of MSC chondrogenic
differentiation [3-7,14,15], the co-administration of these
proteins with MSCs directly into tissues could be pro-
blematic. For example, these proteins generally have
short half-lives in vivo [14], and injection of TGF-b3o r
BMP-2 directly into synovial joints of animal models
has been reported to promote fibrosis and osteophyte
formation [16,17]. These reports highlight a need to
identify alternatives to the established growth factors
(such as the TGF-b/BMP superfamily) that could be co-
administered with MPCs and promote chondrogenic dif-
ferentiation without the potential of adverse side effects,
or the need to include slow release carriers/scaffolds to
extend their time of exposure to the target cells.
Pentosan polysulfate (PPS) is a semi-synthetic sulfated
polysaccharide that has been used for a number of ther-
apeutic applications, including osteoarthritis [18]. More-
over, extensive in vitro and animal model studies using
the sodium or calcium salts of PPS have shown that
these molecules are effective at reducing joint inflamma-
tion, promoting fibrinolysis, stimulating hyaluronan
(HA) synthesis by synovial fibroblasts and stimulating
proteoglycan (PG) synthesis by chondrocytes [18-20].
The PPS salts are also potent inhibitors of granulocyte
elastase and the serine proteinases of the complement
and fibrinolytic systems, as well as downregulating
MMP-13 production at the gene promotor level ([18-21]
and references cited within). Recent studies have also
identified the inhibitory effects of PPS on the cartilage
aggrecanases, ADAMTS4 and ADAMTS5 [22,23], and
their binding to the endogenous inhibitor of these
matrix metalloproteinases, tissue inhibitor of metallo-
proteinases-3, as well as increasing its extracellular half-
life [23,24]. PPS thus possesses the ability to stimulate
the biosynthesis of components of the extracellular
matrix while concomitantly limiting their degradation by
its direct and indirect anti-catabolic effects. As already
mentioned, PPS has been used for the treatment of
osteoarthritis in both veterinary [18,25,26] and human
[18,27] practice, where it is administered via the oral,
systemic or intraarticular routes to provide pain relief
and restoration of joint function.
The present study was undertaken to determine
whether PPS was capable of promoting chondrogenic
differentiation of MPCs in vitro as a first step in the
development of an improved modality for restoring car-
tilage integrity in degenerative synovial joints and the
intervertebral disc. The outcome of these in vitro experi-
ments confirmed that PPS possessed the ability to
induce proliferation and chondrogenic differentiation of
MPCs while inhibiting osteogenic differentiation.
Materials and methods
Drugs
Sodium PPS (batch# Q18) was supplied by bene-Arznei-
mittel GmbH (Munich, Germany), HA (SupaArtz®) was
obtained from Seikagaku Kogyo Company (Tokyo, Japan),
and dextran polysulfate sulfate (molecular weight = 5,000
Da) and heparin were purchased from Sigma-Aldrich
(Sydney, Australia). The sources of all other chemicals and
reagents are identified in the text.
Mesenchymal progenitor cells
STRO-3-positive, human bone marrow-derived MPCs
(Batch# M111sP4) were prepared by Lonza (Walkers-
ville, MD, USA) for Mesoblast Ltd (Melbourne, Austra-
lia), according to the isolation procedure originally
described by Gronthos and colleagues [9,13]. The same
batch of MPCs was used for all of the culture experi-
ments described in this study.
MPC viability and proliferation using the mitochondrial
dehydrogenase cleavage assay
The method used has been described previously [9].
Briefly, primary human MPCs (8 × 10
3 cells/well) were
cultured in 24-well plates in growth media
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ruplicate cultures. On days 1, 3 and 6, the growth media
was removed and replaced with phenol-red-free media
containing the tetrazolium salt, WST-1, and was then
incubated for 2 hours at 37°C in 5% CO2. The intensity
of colour formation was detected using an ELISA micro-
titre plate reader at a wavelength of 450 nm.
Biosynthesis of DNA by MPCs in monolayer cultures
MPCs (100 μl) (2 × 10
4 cells/ml, 2,000 cells/well) were
seeded into wells of a 96-well culture plate and incu-
bated with 200 μl DMEM-high glucose medium con-
taining 10% FBS at 37°C in a humidified atmosphere of
5% CO2 for 24 hours. The medium was then replaced
with 200 μl DMEM-high glucose (+10% FBS) containing
PPS and
3H-thymidine (Perkin-Elmer Life and Analytical
Science, Knoxfield, Victoria, Australia) to afford final
well concentrations of 0, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0 and
20.0 μg/ml and 5 μCi/ml, respectively. Quadruplicate
cultures of each PPS concentration were used. Cultures
were incubated at 37°C in humidified 5% CO2 for 72
hours. The medium was then removed and the wells
were rinsed twice with 200 μl PBS followed by addition
of 50 μl PBS containing 0.25% trypsin (Sigma-Aldrich).
The cultures were incubated at 37°C for 10 minutes and
the released cells were lysed by addition of 200 μld H 2O
to each well for 20 minutes at room temperature. The
3H-DNA in the cell lysates was separated from unincor-
porated
3H-thymidine using glass fibre filters and a cell
harvester (Skatron Instruments AS, Lier, Norway). The
filters were then air-dried and punched into scintillation
vials. Scintillation cocktail liquid (3 ml/vial) was added
and vials were vortexed for 30 to 40 seconds. The radio-
activity of
3H incorporated into the DNA of replicating
MPCs was determined by scintillation counting (Tricarb
2900 TR; Perkin-Elmer Life and Analytical Science).
Pentosan polysulfate and MPC apoptosis
The method used has been described previously [28].
Briefly, single-cell suspensions of cultured MPCs (2 ×
10
4 cells/well) were plated in serum-free media supple-
mented with 0, 1, 2, 5 and 10 μg/ml PPS. MPC apopto-
sis was induced by the addition of a combination of 30
ng/ml IL-4 and 30,000 U/ml IFNg/well. Following 5
days of culture, cells were harvested by trypsinisation
and MPC viabilities were assessed by Annexin V stain-
ing as previously described [28].
Concentration effects of PPS on the biosynthesis of
proteoglycans by MPCs in micromass cultures over 5, 7
and 10 days
MPCs were established in micromass cultures (MMC)
using the methodology described previously [29-31].
Ten microlitres of a single-cell suspension of MPCs (1 ×
10
7 cells/ml) in DMEM-high glucose + 10% FBS were
applied to the centre of individual wells of 24-well cul-
ture plates (Cellstar®; Greiner Bio-One GmbH, Fricken-
hausen, Germany). After incubation at 37°C in 5% CO2
for 3 hours, 900 μl DMEM-high glucose + 10% FBS was
added and plates were then incubated for a further 20
hours. The media was replaced with DMEM-high glu-
cose + 10% FBS containing PPS at final well concentra-
tions of 0.0, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0 and 20.0 μg/ml,
and cultures were maintained with media changes con-
taining the same PPS concentrations every 48 hours.
Two days prior to culture termination on days 3, 5,
and 7, the media was replaced with media containing
35S-H2SO4 (Perkin-Elmer Life and Analytical Science) at
af i n a l
35SO4 well concentration of 5 μCi/ml together
with the same concentrations of PPS and culture contin-
ued for a further 2 days. On days 5, 7 and 10 media
were collected and cells released with 2.5% trypsin/ethy-
lenediamine tetraacetic acid and collected by centrifuga-
tion. After washing with PBS, the cell pellets were
stored at -70°C for RNA and DNA analysis. The super-
natants and washings were combined and digested with
Papain (Sigma-Aldrich) (2.5 mg/ml in 0.1 M Na acetate,
5 mM ethylenediamine tetraacetic acid, pH 6.0) at 65°C
for 2 hours.
Aliquots (n = 6) of the digest were transferred to
96-well plates and the
35S-sulfated glycosaminoglycans
(
35S-GAGs) were separated from the
35SO4 by addition
of 20 μl of 5% cetyl pyridinium chloride + 10 μlo f1
mg/ml chondroitin sulfate C (both from Sigma Chemi-
cals, Sydney, Australia). The precipitate
35S-GAG-cetyl
pyridinium chloride complexes were collected by filtra-
tion through glass fibre discs using a cell harvester
(Skatron Instruments AS). The radioactivity of the
35S-GAG-cetyl pyridinium chloride complexes was
determined by scintillation counting (Tricarb 2900 TR;
Perkin-Elmer Life and Analytical Science). The incor-
poration of
35S into newly synthesised GAGs was nor-
malised to the culture DNA content [32]. Results were
calculated as
35S-GAG-Decays Per Minute/μg DNA and
then expressed as a percentage of control cultures (with-
out PPS) that were set at 100%.
Concentration effects of PPS, hyaluronan, dextran sulfate
and heparin on the biosynthesis of proteoglycans by
MPCs in MMC over 5 days
The MMC, established as described above, were main-
tained in culture for 3 days in the presence of PPS, HA,
dextran sulfate (DS) or heparin at concentrations of 0.0,
0.1, 0.5, 1.0, 2.5, 5.0, 10.0 and 20.0 μg/ml, and were then
incubated with
35S-H2SO4 (Perkin-Elmer Life and Ana-
lytical Science) at a final
35SO4 well concentration of
5 μCi/ml for an additional 2 days in the presence of
the drugs. Incorporation of
35Si n t oS - G A G sw a s
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as the percentage of controls cultured in the absence of
the drugs.
Concentration effects of PPS on proteoglycan production
by MPCs in MMC over 5, 7 and 10 days as assessed by
staining with Alcian blue
M i c r o m a s sc u l t u r e so fM P C s( 1 0
7 cells/ml, 8 μl/micro-
mass) were established on eight-well slides (Lab-Tek®
Chamber Slide, Permanox®; Grand Island, NY, USA) and
maintained in the presence of 0 to 20 μg/ml PPS for 5,
7 and 10 days as described above for the PG synthesis
assays. At the end of each culture period, the medium
was removed and the cells and matrix were fixed with
HistoChoice MB (Amresco, Solon, OH, USA). After
washing in distilled water for 1 minute, the cultures
were stained with 1% Alcian blue, 8GX (Sigma Chemical
Company, Sydney, Australia) (dissolved in 3% acetic acid
at pH 2.5) for 30 minutes. Staining was terminated by
washing the slides with running tap water for 2 minutes,
and then rinsing in distilled water for a further 2 min-
utes. After dehydrating through three changes of abso-
lute ethanol, allowing 3 minutes for each change, the
stained micromass cultures were observed microscopi-
cally and the images captured using a microscope digital
camera (Nikon Eclipse 80i; Coherent Sciences, Adelaide,
Australia).
Concentration effects of PPS on collagen type II
production by MPCs in MMC over 5, 7 and 10 days
MMC of MPCs were established in 24-well culture
plates at a starting density of 8 × 10
4 cells/micromass in
t h ep r e s e n c eo f0t o2 0 . 0μg/ml PPS as described above
for the PG synthesis assays. On days 5, 7 and 10, media
were removed and cultures were fixed with Histochoice
MB (Amresco) for 20 to 30 minutes at room tempera-
ture and processed for immunohistochemical staining of
collagen type II as described by Denker and colleagues
[29]. A human collagen type II monoclonal antibody
(Clone II-4II, IgG, ImmunO™; MP Biomedicals Australia,
Seven Hills, NSW, Australia) dissolved in PBS/10%
Hepes-Triton 10% FBS followed by a goat anti-mouse
AP-conjugated secondary antibody (2 mg/ml) (Invitro-
gen Australia Pty Ltd, Mulgrave, Victoria, Australia) was
used. After washing (3 × 5 minutes) with PBS, 200 μl5 -
bromo-4-chloro-3’-indoyl phosphate/buffer + nitroblue
tetrazolium salt was added and the cultures incubated at
3 7 ° Cf o r1 5t o2 0m i n u t e s .A f t e rt h ep u r p l ec o l o u rw a s
fully developed (15 to 20 minutes) the wells were
washed with running water that was discarded. The
dried plates and wells were then photographed with a
digital camera (Nikon D40×) and the digital images
were analysed by Image J® public domain software using
a personal computer.
Concentration effects of PPS on proteoglycan, collagen
type I and collagen type II deposition by MPCs in 5-day,
7-day and 10-day pellet cultures
MPCs (3 × 10
5 cells) were seeded in sterile 2 ml screw-
capped plastic centrifuge tubes (Scientific Specialities Inc.,
Lodi, CA, USA) to which 1 ml DMEM-high glucose med-
ium + 10% FBS was added. Cells were centrifuged at
500 × g for 10 minutes at room temperature, the caps
were loosened and the cultures maintained at 37°C in a
5% CO2 atmosphere to establish the pellets. After 24
hours the medium in each tube was removed and replaced
with 1.0 ml DMEM-high glucose medium + 10% FBS con-
taining PPS at final concentrations of 0.0, 0.1, 0.5, 1.0, 2.5,
5.0, 10.0 and 20.0 μg/ml, respectively. The pellet cultures
were maintained under these conditions for 5, 7, and 10
days with medium changes with and without PPS every 2
to 3 days. Triplicate cultures were established for each of
the PPS concentrations nominated. At the end of each cul-
ture period, the medium was aspirated and pellets were
fixed by addition of 200 μl Histochoice MB (Amresco) for
45 minutes at room temperature, rinsed with 70% ethanol
once and stored in 70% ethanol prior to paraffin embed-
ding and processing for histological and immunohisto-
chemical examination as described previously [9].
De-paraffinised 5 μm sections were stained with 0.1%
Toluidine blue (Sigma Chemicals) or used for immuno-
histochemistry. Briefly, 5 μm serial sections were
blocked for 2 hours with either 5% normal goat serum
or 5% rabbit serum and were then incubated overnight
at 4°C with the primary antibodies: goat anti-human
immunoglobulin collagen type I (0.8 μg/ml; Chemicon
International, Temecula, CA, USA), mouse anti-human
IgG1 collagen type II (1:100; Chemicon International),
or corresponding control antibodies goat immunoglobu-
lin negative control (0.8 μg/ml; Caltag Laboratories, Bur-
lingame, CA, USA) and mouse IgG1 (1B5) negative
control (0.8 μg / m l ,k i n d l yp r o v i d e db yP r o f .L .A s h -
mann, University of Newcastle, New South Wales, Aus-
tralia). The sections were washed three times with PBS
before adding the secondary antibodies of either conju-
gated goat anti-mouse IgG biotin (2.5 μg/ml; Southern
Biotechnologies, Birmingham, AL, USA) or conjugated
rabbit anti-goat immunoglobulin biotin (2.5 μg/ml; Vec-
tor Laboratories Inc. Burlingame, CA, USA), for 90 min-
utes at room temperature. After washing three times in
PBS, the sections were incubated with streptavidin
horseradish peroxidase (2 μg/ml; Chemicon Interna-
tional) for 1 hour at room temperature in a dark, moist
chamber. The sections were then washed three times
with PBS before incubating with the liquid DAB + Sub-
strate Chromagen System according to the manufac-
turer’s instructions (Dako, Carpinteria, CA, USA). After
rinsing in distilled water, the sections were counter-
stained with Mayer’s haematoxylin before mounting.
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10 days
M P C sw e r ee s t a b l i s h e di nM M Ca n dc u l t u r e di nt h e
presence of 0.0, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0 and 20.0 μg/
ml PPS as described above. Experiments were termi-
nated 7 and 10 days post seeding. Media were removed
and centrifuged (12,000 × g/10 minutes), and triplicate
aliquots were used to determine the HA concentrations
using a commercially available ELISA kit (MP Biomedi-
cals Asia Pacific Pte Ltd, Singapore) by following the
manufacturer’s instructions. To the remaining micro-
mass culture in each well, 200 μl of 1 mg/ml collagenase
(Sigma Chemicals) in collagenase buffer (66.7 mM NaCl,
6.7 mM KCl, 4.8 mM CaCl2, 10 mM HEPES (pH 7.4))
were added. The plates were incubated with gentle shak-
ing at 37°C for 2.5 hours to release the cells. The cells
and digested matrix were then placed in a boiling water
bath for 30 minutes to denature the collagenase, cooled
then centrifuged at 12,000 × g for 5 minutes. Triplicate
aliquots of the supernatants were used to determine the
HA concentrations within the matrices using the ELISA
kit. Aliquots of the cell digests from each culture were
used to determine the DNA content as described pre-
viously [32]. Results were expressed as micrograms per
millilitre of HA per microgram of DNA to normalise for
changing cell numbers.
Real-time PCR
Real-time quantitative PCR was used to assess MPC
expression of selected genes, as listed in Table 1, using
the RT
2Real-Time™ SYBR Green/Rox PCR master mix
(SABiosciences Corporation, Frederick, MD, USA)
according to the manufacturer’s instructions. The typical
Rotor-Gene (Corbett Research, Mortlake, NSW, Austra-
lia) cycling parameters used were: 50°C for 2 minutes;
95°C for 15 minutes (95°C for 15 seconds, 60°C for 26
seconds, 72°C for 10 seconds - 40 to 48 cycles); and 72°
C for 3 minutes. The primer sets used for these studies
are presented in Table 1. The cycle threshold values
were used to calculate the relative mRNA copy number.
All PCR reactions were performed in triplicate and vali-
dated by the presence of a single peak in the melt curve
analysis. All expression was normalised against the
housekeeping gene, b-actin.
Concentration effects of PPS on MPC differentiation when
cultured in an osteoinductive medium
The culture conditions required for the osteoblastic dif-
ferentiation of MPCs and the deposition of mineralised
bone matrix in vitro have been previously described
[1,9]. The same osteoinductive medium was used for the
present experiments and consisted of a-MEM supple-
mented with 2% (v/v) foetal calf serum, 1.8 mM
KH2PO4,1 0
-7 M dexamethasone, sodium phosphate, 50
IU/ml penicillin, 50 μg/ml streptomycin, 1 mM sodium
pyruvate, 100 mM L-ascorbic acid 2-phosphate, 2 mM
L-glutamine and 10 mM HEPES buffer. MPCs were
seeded into 96-well plates at 8 × 10
3 cells/well and
allowed to reach ≥ 90% confluence prior to the addition
of osteoinductive media containing PPS at concentra-
tions of 0.0, 1.0, 2.0, 5.0 and 10 μg/ml. Cells were cul-
tured at 37°C in the presence of a humidified
atmosphere of 5% CO2 with twice-weekly media changes
for 4 weeks. The total mineral content per well was
assessed from the calcium levels per DNA in each well
[26]. Absolute absorbance was determined by measuring
against a series of DNA standards at 350 nm in a LS55
Luminescence Spectrometer (Perkin Elmer Life and
Analytical Science).
Concentration effects of PPS on MPC differentiation when
cultured in an adipogenic medium
MPCs were cultured in adipogenic-inductive media
[27,33] comprised of complete a-MEM supplemented
with 0.5 mM 3-isobutyl-1-methyl-xanthine, 60 μM indo-
methacin, and 0.5 μM hydrocortisone in the presence of
concentrations of PPS of 0.0, 1.0, 2.0, 5.0 and 10 μg/ml.
The inductive media was changed twice weekly for a
period of 4 weeks. Cells were stained for the presence of
Table 1 Primer sequences used for real-time PCR to
evaluate gene expression by mesenchymal precursor
cells
Gene Primer sequences (5’ to 3’)
Aggrecan Forward: CTG CTT CCG AGG CAT TTC
Reverse: GCT CGG TGG TGA ACT CTA GG
Type I collagen Forward: AGG GTC CCA ACG AGA TCG AGA TCC
Reverse: TAC AGG AAG CAG ACA GGG CCA ACG TCG
Type II collagen Forward: GCC TGG TGT CAT GGG TTT
Reverse: GTC CCT TCT CAC CAG CTT TG
Sox-9 Forward: AGG TGC TCA AAG GCT ACG AC
Reverse: GCT TCT CGC TCT CGT TCA GA
Type X collagen Forward: AAT GCC CAC AGG CAT AAA AG
Reverse: AGG ACT TCC GTA GCC TGG TT
IGFBP-3 Forward: CGC CAG GAA ATG CTA GTG AG
Reverse: ACG GCA GGG ACC ATA TTC T
IGFBP-5 Forward: GAG AAA GCC CTC TCC ATG TG
Reverse: TCA CGG GAG TCT CTC TCG AT
Noggin Forward: ATC GAA CAC CCA GAC CCT ATC
Reverse: TCT AGC CCT TTG ATC TCG CTC
CBFA-1 (RUNX2) Forward: GTG GAC GAG GCA AGA GTT TCA
Reverse: CAT CAA GCT TCT GTC TGT GCC
b-Actin Forward: GAT CAT TGC TCC TCC TGA GC
Reverse: GTC ATA GTC CGC CTA GAA GCA T
Primer sequences used for real-time PCR to evaluate gene expression by
mesenchymal precursor cells maintained in micromass cultures in the absence
and presence of pentosan polysulfate for 7 and 10 days. IGFBP, insulin-like
growth factor binding protein.
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7.4) to avoid disruption of the cell monolayer. Cells
were fixed in phosphate-buffered formalin for 15 min-
utes at 21°C. The fixative was subsequently removed
and lipid stained by addition of 100 μl freshly filtered
Oil Red O (3 mg/ml; MP Biomedicals Australia, Seven
Hills, NSW, Australia) for ≥ 2 hours at ambient tem-
perature. Cells were rinsed three times with water and
counterstained with Mayer’s haematoxylin (Lillie’s modi-
fication). Haematoxylin stains were aspirated and
replaced by water, and any Oil Red O-positive adipo-
cytes were examined under a light microscope and
photographed with a DP20-56 Olympus camera.
Statistical analysis of data
The statistical analysis of the data generated in all assays
that compared the effects of drug groups at different
concentrations on MPC response relative to control (no
drugs) response was undertaken using one-way analysis
of variance with a Bonferroni multiple comparison post
hoc test and Student’s unpaired t test. Groups were con-
sidered significantly different from controls when P <
0.05. Each data point represents the mean ± standard
deviation of three to six samples unless otherwise indi-
cated. Data analysis and graphical representations of
results were undertaken using the Instat® and Microsoft
Excel® software packages.
Results
MPC viability and proliferation in monolayer culture
Using the WST-1 mitochondrial dehydrogenase cleavage
assay at day 6, viable MPC numbers were significantly
increased in the cultures containing 1 to 10 μg/ml PPS
(P < 0.01) (Figure 1a). Similarly, using
3H-hymidine
incorporation, a significant increase in MPC numbers
w a so b s e r v e da t1t o5μg/ml (P < 0.05) after 3 days of
culture (Figure 1b). To determine whether the increase
in MPC number was related to the anti-apoptotic prop-
erties of PPS, MPC monolayer cultures were exposed to
IL-4 and IFNg [31] in the absence and presence of the
drug for 5 days. These experiments showed that PPS
over the concentration range of 1 to 10 μg/ml dimin-
ished MPC apoptosis by an average of 38% relative to
the control cultures containing no PPS (Figure 1c).
Effects of PPS on proteoglycan synthesis in 5-day, 7-day
and 10-day MPC MMC
The incorporation of PPS in MPC MMC stimulated PG
biosynthesis in a concentration-dependant manner that
also varied with the duration of culture (Figure 2). In 5-
day MMC, maximal stimulation (130%) of PG synthesis
occurred at 2.5 μg/ml PPS (P < 0.0001), while 5.0 μg/ml
PPS was required to achieve maximal stimulation (160%,
P < 0.01) on day 7. Stimulation (150%, P <0 . 0 5 )w a sa l s o
observed, however, with the lower concentration of 2.5
μg/ml PPS in this time period. A similar concentration-
dependent response to PPS as that for day 7 was found
for the 10-day MPC cultures, with a maximal production
of
35S-GAGs with 5.0 μg/ml PPS (P < 0.05) (Figure 2).
Effects of PPS, hyaluronan, dextran sulfate and heparin
on proteoglycan biosynthesis by MPCs
As noted above, in the 5-day cultures (Figure 2) PPS
exhibited a concentration-dependent stimulation of PG
biosynthesis by MPCs, with a maximum effect being
observed at 2.5 μg/ml PPS, with a progressive decline in
stimulation at higher concentrations. Nevertheless, sig-
nificantly higher levels of
35S-GAGs than controls were
still produced by the MPCs at 5.0 and 10 μg/ml PPS
(P <0 . 0 5 )( F i g u r e3 a ) .U n d e rt h es a m ec u l t u r ec o n d i -
tions, heparin had no effect (Figure 3b) while HA stimu-
lated PG synthesis at 1 μg/ml (P < 0.01) but significantly
inhibited synthesis at concentrations of 5 to 20 μg/ml
(P < 0.05 to 0.0005) (Figure 3c). DS was found to
strongly inhibit PG synthesis over the concentration
range of 1 to 20 μg/ml (P < 0.05 to 0.005) (Figure 3d).
Effects of PPS on proteoglycan deposition by MPCs in
MMC as assessed by Alcian blue staining
Although the micromass cultures of MPCs established
on the Nunc eight-well Lab-Tek® Chamber Slides did
not grow as well as on the Greiner Cellstar® 24-well
plates, a gradation of staining for PGs with Alcian blue
was found to be proportional to the incubation time
and PPS concentrations used. The strongest staining
was observed in the 10-day cultures, with the most
intense Alcian blue staining evident at concentrations ≥
2.5 μg/ml PPS (Figure 4).
Effects of PPS on the deposition of collagen type II by
MPCs in MMC as assessed by immunohistochemistry
Deposition of collagen type II in the fixed matrices of
MPC MMC was successfully demonstrated and semi-
quantified using the immunostaining technique described
by Denker and colleagues [29]. For the 7-day and 10-day
culture periods, a progressive stimulation of collagen
type II synthesis was observed with PPS concentrations
up to 5 μg/ml followed by a marked decline at 10 and 20
μg/ml PPS (Figure 5b, c, d). In the 5-day cultures, lower
but significant (P < 0.001 to 0.05) stimulation of collagen
type II synthesis by MPCs was still evident at PPS con-
centrations up to 20 μg/ml (Figure 5a).
Effects of PPS on proteoglycan, collagen type I and
collagen type II deposition by MPCs in 5-day, 7-day and
10-day pellet cultures
Pellets were formed by all cultures irrespective of the
time of incubation and the absence or presence of PPS.
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Page 6 of 17While no attempt was made to quantify the differences,
larger more robust pellets were generally observed in
the presence of PPS. Moreover, PPS also conferred a
stronger and more uniform Toluidine blue staining for
PGs, as exemplified in the photomicrographs of pellets
shown in Figure 6a, b (top panels). Compact pellets and
uniformity of staining in PPS co-cultures was also
observed for matrix collagens in the serial sections used
for immunohistochemical staining of these proteins.
Moreover, the intensity of staining for collagen type II
was greater than collagen type I in sections of pellets
g r o w ni nt h ep r e s e n c eo f2 . 5μg/ml PPS compared with
control pellets cultured without PPS (compare Figure 6a
with Figure 6b, bottom two panels).
Effects of PPS on the synthesis of hyaluronan by MPCs
In the absence of PPS, MPCs were found to elaborate HA
into the media and extracellular matrix in equal amounts
in the 7-day MMC, but this distribution was altered in the
presence of PPS with increasing amounts being deposited
in the matrix (Table 2). This increase was significant at 5
and 10 μg/ml PPS (P < 0.001) while media levels declined
accordingly (P < 0.05) (Table 2). In the 10-day MPC con-
trol cultures, higher levels of HA were detected in the
matrix than in the culture media (P < 0.05). In the pre-
sence of all concentrations of PPS, HA levels in the media
at 10 days were less than control media levels (P <0 . 0 5 )
(Table 2). Matrix deposition of HA, however, was found to
be higher than controls at PPS over the concentration
Figure 1 Mesenchymal precursor stem cell viability and proliferation in monolayer culture. (a) Bar graph showing the concentration-
dependent effect of pentosan polysulfate (PPS) on mesenchymal precursor stem cell (MPC) proliferation. Primary MPCs were cultured in 24-well
plates in growth media supplemented with PPS at the indicated concentrations (n = 3). On days 1 (black columns), 3 (white columns) and 6
(hatched columns), the cells were incubated with the tetrazolium salt WST-1 for 2 hours at 37°C to produce a formazan dye. Absorbance at 450
nm for each time point is shown for the indicated concentrations of PPS. Data expressed as mean ± standard error of the mean. A statistically
significant increase in proliferation was observed on day 6 at concentrations of PPS in excess of 1 μg/ml (*P < 0.01). (b) Concentration effects of
PPS on DNA synthesis in 3-day monolayer cultures of MPCs (n = 3). Data expressed as mean ± standard deviation. Significant elevation in DNA
synthesis was observed at PPS concentrations of 1, 2.5 and 5 μg/ml relative to control cultures (P < 0.01). (c) Flow cytometric analysis profiles
showing the inhibitory effects of different concentrations of PPS on MPC apoptosis induced by the addition of a combination of 30 ng/ml IL-4
plus 30,000 U/ml IFNg. Following 5-day culture, cells were harvested by trypsinisation and viabilities assessed by Annexin V staining (n = 3 per
PPS concentration). An average 38% reduction in apoptosis was observed when MPCs were cultured at PPS concentrations >1 μg/ml. DPM,
Decays Per Minute.
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Page 7 of 17Figure 2 Effects of pentosan polysulfate on proteoglycan synthesis in mesenchymal precursor stem cell micromass cultures. Bar graphs
showing the temporal and concentration effects of pentosan polysulfate (PPS) on the biosynthesis of proteoglycans (determined as sulfated
glycosaminoglycans (
35S-GAGs)) by mesenchymal precursor stem cells (MPCs) in micromass cultures for 5, 7 and 10 days. Data (mean ± standard
deviation) presented as percentage of control calculated from the
35S-GAG DPM/μg DNA values at each PPS concentration (n = 6).
‡P < 0.05, *P
< 0.01; **P < 0.001; ***P < 0.0001 relative to control cultures.
Figure 3 Effects of pentosan polysulfate, hyaluronan, dextran sulfate and heparin on mesenchymal precursor cell proteoglycan
biosynthesis. Bar graphs showing the concentration-dependent effects of (a) pentosan polysulfate (PPS), (b) heparin, (c) hyaluronan (HA) and
(d) dextran sulfate (DS) on prosteoglycan (PG) synthesis by mesenchymal precursor stem cells (MPCs) in micromass cultures for 5 days. Data
(mean ± standard deviation) presented as percentage of control calculated from the sulfated glycosaminoglycan (
35S-GAG) Decays Per Minute/
μg DNA values at each drug concentration (n = 3).
‡P < 0.05, *P < 0.01; **P < 0.001; ***P < 0.0001 relative to control values.
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Page 8 of 17Figure 4 Effects of pentosan polysulfate on proteoglycan deposition by mesenchymal precursor cells in micromass cultures.
Photomicrographs of mesenchymal precursor stem cell micromass cultures maintained in the absence and presence of pentosan polysulfate
(PPS) for 10 days then stained with Alcian blue as described in the text: (a) 0.0 μg/ml PPS, (b) 1.0 μg/ml PPS, (c) 2.5 μg/ml PPS, (d) 5.0 μg/ml
PPS, (e) 10.0 μg/ml PPS, and (f) 20 μg/ml PPS. Note the more intense staining with the dye at concentrations ≥ 2.5 μg/ml PPS, indicating the
presence of higher levels of proteoglycans in these cultures.
Figure 5 Effects of pentosan polysulfate on collagen type II deposition by micromass culture mesenchymal precursor cells. Bar graphs
showing the concentration-dependent effects of pentosan polysulfate (PPS) on collagen type II deposition by mesenchymal precursor stem cells
(MPCs) in micromass cultures (MMC) for (a) 5 days, (b) 7 days and (c) 10 days as determined by digital analysis of colour-intensity images of the
5-bromo-4-chloro-3’-indoyl phosphate/buffer + nitroblue tetrazolium salt stained conjugate to collagen type II applied to fixed MMC. n = 3 for
each PPS concentration. Data expressed as mean ± standard deviation. (d) Digital photograph of the stained 7-day MMC cultures in 24-well
culture plates after processing as described in the text showing the staining intensity in relation to PPS concentration.
‡P < 0.05, *P < 0.01;
**P < 0.001; ***P < 0.0001 relative to control.
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Page 9 of 17range of 1.0 to 20 μg/ml but was only significant at 0.1 and
0.5 μg/ml PPS (P < 0.001) (Table 2).
Real-time quantitative PCR
For the most part, SOX-9 gene expression by MPCs was
observed to be significantly upregulated by PPS at con-
centrations ≥ 0.05 μg/ml (P < 0.01) in 7-day MMC cul-
tures (Figure 7a). In 10-day MMC, a strong upregulation
of SOX-9 gene expression was observed at 10 μg/ml (P <
0.001), but this effect declined to basal levels at 20 μg/ml
PPS (Figure 7a). Aggrecan gene expression in day-7
MMC followed a similar pattern to that observed for
SOX-9, with the highest expression relative to control
MMC occurring at 20 μg/ml PPS (P < 0.001) (Figure 7b).
In the 10-day MPC cultures, however, upregulation of
the aggrecan gene occurred over the PPS concentration
Figure 6 Effects of pentosan polysulfate on proteoglycan, collagen type I and collagen type II deposition in pellet cultures.
Photomicrographs of sections of mesenchymal precursor stem cell (MPC) pellet cultures showing the effects of pentosan polysulfate (PPS) on
chondrocyte development. Representative 5 μm serial tissue sections are shown of cells cultured as pellets for 10 days in (a) the absence of PPS
(top nine panels) or (b) the presence of PPS (bottom nine panels). Control pellet sections (a) appeared fragmented with less intense toluidine
blue staining for proteoglycans in comparison with those pellet cultures treated with 2.5 mg/ml PPS (b). Immunohistochemical staining
confirmed higher levels of the cartilage matrix protein and collagen type II, and lesser levels of collagen type I in pellet cultures treated with
2.5 μg/ml PPS (b) than in the corresponding control pellet cultures (a).
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Page 10 of 17range of 0.1 to 5.0 μg/ml (P < 0.01 to 0.001) but
decreased at 10 and 20 μg/ml (Figure 7b). Collagen type
II expression in MPCs was low and found to be only
increased in the presence of 10 and 20 μg/ml PPS in 7-
day cultures (P < 0.05) but was elevated at lower concen-
trations (0.1 and 1.0 μg/ml PPS) (P < 0.01) in the 10-day
cultures (Figure 7c). Although collagen type I expression
was considerably higher than collagen type II in all MPC
cultures, it declined significantly in the 7-day and 10-day
MMC containing PPS at all concentrations examined (P
< 0.05 to 0.001) (Figure 7d).
The gene marker of chondrocyte hypertrophy, col-
lagen type X, was suppressed in the 10-day MMC by
PPS at concentrations of 0.1, 0.5 and 2.5 μg/ml (P <
0.05 to 0.001) (Figure 7e), while the osteogenesis marker
gene, RUNX2, required the higher concentrations of 2.5
to 10.0 μg/ml to achieve significant downregulation (P <
0.05) (Figure 7f). Noggin expression was suppressed by
PPS in 7-day cultures at 0.1 μg/ml (P < 0.05) and in 10-
day cultures over the concentration range of 2.5 to 10
μg/ml PPS (P < 0.05 to 0.001) (Figure 7g).
Effects of PPS on the differentiation of human MPCs
Previous studies have shown that the STRO-3-positive
human bone marrow-derived MPCs used in these stu-
dies undergo differentiation into osteocytes or adipo-
cytes when cultured with the appropriate inductive
media [9,13]. In the present study, however, co-culturing
MPCs with 5 or 10 μg/ml PPS in an osteogenic media
for 28 days suppressed their differentiation into the
osteocyte/osteoblast lineage (P < 0.01) (Figure 8). In the
presence of the adipogenic medium, PPS was found to
enhance adipogenic differentiation of MPCs. This effect
was significant at all PPS concentrations examined
(P < 0.01) (Figure 9).
Discussion
The present studies have demonstrated that PPS induces
in vitro proliferation and chondrogenic differentiation of
MPCs in a concentration-dependent and time-depen-
dent manner. These activities were manifest over a PPS
concentration range of 1 to 20 μg/ml, with 2.5 and 5.0
μg/ml showing the strongest effects. At the higher con-
centration of 20 μg/ml PPS, however, in 7-day cultures
a possible decline in MPC chondrogenesis was signalled
by the upregulation of collagen type X gene expression
and decreased expression of RUNX2, but these varia-
tions were not statistically significant. Similar dose-
dependent changes in chondrogenic differentiation have
been reported with glucosamine when cultured with
MSCs in the presence of TGF-b [34]. The enhanced
production of the cartilage-specific phenotypic markers,
PGs and type II collagen, by MPCs in the presence of
PPS was demonstrated in MMC using a quantitative
radiochemical assay and semiquantitatively by immunos-
taining with a type II collagen antibody. These assays
were supported qualitatively by the positive staining of
the MMC for the presence of PGs using Alcian blue dye
and in histological sections of pellet cultures by Tolui-
dine blue dye and type II collagen antibody staining.
Significantly, immunostaining of serial sections for col-
lagen type I clearly demonstrated diminished levels of
this protein in pellets grown in the presence of PPS.
The aforementioned findings were consistent with the
real-time PCR results, which showed the corresponding
upregulation of SOX-9, aggrecan and type II collagen gene
expression but downregulation of type I collagen expres-
sion by MPCs cultured in the presence of PPS. In addition,
MPC expression of gene markers for chondrocyte hyper-
trophy and osteogenesis, type X collagen and the key tran-
scription factor for bone formation, RUNX2, were
Table 2 Concentration effects of pentosan polysulfate on hyaluronan deposition in human mesenchymal progenitor
cell micromass cultures
PPS concentration (μg/ml) HA concentration (μg/ml)
Media 7 days Matrix 7 days Media 10 days Matrix 10 days
Control 0.0 1.54 ± 0.03 1.58 ± 0.01 1.55 ± 0.06 2.10 ± 0.03
§
0.1 1.34 ± 0.05
# 1.76 ± 0.26 1.30 ± 0.08
# 1.64 ± 0.07
#
0.5 1.34 ± 0.11
# 1.74 ± 0.07 1.22 ± 0.17
# 1.89 ± 0.01
#
1.0 1.09 ± 0.05
# 1.98 ± 0.29 1.23 ± 0.06
# 2.42 ± 0.32
2.5 1.50 ± 0.17 1.78 ± 0.23 1.32 ± 0.12
# 2.24 ± 0.39
5.0 1.28 ± 0.05
# 2.16 ± 0.20* 1.33 ± 0.07
# 2.27 ± 0.24
10.0 1.25 ± 0.03
# 2.39 ± 0.32 0.84 ± 0.09
# 2.57 ± 0.31
20.0 1.36 ± 0.05
# 2.31 ± 0.33* 1.32 ± 0.06
# 2.54 ± 0.04**
Statistical significance
#PPS < control (P < 0.05) *PPS > control (P < 0.05)
#PPS < control (P < 0.05)
§Matrix > media (P < 0.05),
#PPS < control (P < 0.05),
**PPS > control (P < 0.005)
Concentration effects of pentosan polysulfate (PPS) on hyaluronan (HA) deposition in the media and matrix of 7-day and 10-day micromass cultures of human
mesenchymal progenitor cells (MPCs). Data are mean ± standard deviation of triplicate culture values.
Ghosh et al. Arthritis Research & Therapy 2010, 12:R28
http://arthritis-research.com/content/12/1/R28
Page 11 of 17markedly downregulated by PPS at concentrations that
induced the strongest MPC chondrogenic differentiation.
Furthermore, the experiments designed to promote MPC
osteogenic differentiation using osteogenic-inductive cul-
ture media failed to achieve this effect in the presence of 5
and 10 μg/ml PPS, although adipogenic differentiation was
increased in the adipogenic culture medium.
The establishment of MSCs in pellet cultures or MMS
has been shown to favour their condensation, prolifera-
tion and differentiation along the chondrocytic lineage
[6,7,28-30,35]. In the absence of media supplemented
with growth factors such as TGF-b3, BMPs, fibroblast
growth factor, insulin-like growth factor (IGF) or insu-
lin, however, MSCs normally required several weeks to
exhibit significant chondrogenic differentiation. More-
over, such cultures generally progressed towards a
mixed cartilage phenotype with the upregulation of type
I collagen and type X collagen [35]. In this context, it
should be noted that the chondrogenic differentiation of
MPCs mediated by PPS was demonstrated without the
addition of growth factors or other chondroinductive
supplements and failed to upregulate type I collagen and
collagen type X expression. Furthermore, our unpub-
lished studies using MPCs grown in collagen sponges or
murine MSCs in MMC or pellet cultures have shown
that PPS acts synergistically with insulin or TGF-b3i n
promoting chondrogenic differentiation of these cells.
To our knowledge this is the first study to show that
adult MPCs in high-density MMC synthesised HA. In
the 7-day control cultures HA was localised equally
between the media and extracellular matrix, but in the
10-day cultures more HA was deposited in the
Figure 7 Effects of pentosan polysulfate on gene expression by mesenchymal precursor stem cells in micromass cultures. Bar graphs
showing the concentration effects of pentosan polysulfate (PPS) on (a) SOX-9, (b) Aggrecan, (c) collagen type II, (d) collagen type I, (e) collagen
type X, (f) RUNX2 (Cbfa1) and (g) Noggin gene expression by mesenchymal precursor stem cells (MPCs) in micromass cultures for 7 and 10 days
as determined by real-time quantitative PCR. n = 3 for each PPS concentration. Data expressed as mean ± standard deviation for each PPS
concentration after normalising for the expression of the housekeeping gene, b-actin.
#P < 0.05, *P < 0.01, **P < 0.001, ***P < 0.0001 gene
expression relative to control.
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PPS showed increased deposition of HA in the matrix
while levels in the media declined proportionally. A pos-
sible explanation for this shift in distribution could
relate to the interaction of HA with newly synthesised
PG monomers from the differentiating MPCs to form
the PG aggregates characteristic of hyaline cartilage.
Enhanced binding of HA to pericellular hyaladherins
and MPC receptors (for example, CD44) upregulated by
PPS, however, could also be a consideration.
Using other related polysaccharides in the PG bio-
synthesis assay provides evidence for the specificity of
PPS as a promoter of MSC chondrogenesis. In 5-day
MPC MMC in which HA was substituted for PPS, sti-
mulation of PG synthesis occurred at 1 μg/ml but sup-
pression was observed at concentrations > 5 μg/ml. DS,
which has a similar charge density and molecular weight
to PPS, strongly inhibited PG synthesis by MPC at all
concentrations > 1 μg/ml, while heparin showed no
effect over the concentration range used.
Native HA is known to have negative effects on chon-
drogenesis during limb morphogenesis [36] but there
are limited data available on its effects on adult MSCs.
In alginate bead cultures of MSCs, incorporation of high
Figure 8 Effects of pentosan polysulfate on human mesenchymal precursor stem cell differentiation: mineralisation assay.P r i m a r y
mesenchymal precursor stem cells (MPCs) were cultured in non-osteoinductive growth media (media control) or in osteoinductive conditions in
the absence or presence of pentosan polysulfate (PPS) at the indicated concentrations. n = 3 for each PPS concentration studied. (a)
Concentration of acid-solubilised calcium per well determined relative to the total amount of DNA per well. Data expressed as mean ± standard
error of the mean for day 28. (b) Phase-contrast photomicrographs of cultures showing absence of mineralisation in the co-cultures with PPS (×
20). A statistically significant decrease (P < 0.01) in mineralised matrix formation was observed for PPS concentrations of 5 and 10 μg/ml. *P <
0.01 relative to controls.
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Page 13 of 17molecular weight HA into the beads enhanced chondro-
genic differentiation at concentrations of 50 to 1,000 μg/
ml, but the effects at lower concentrations were not
reported [37]. MSCs grown in pellet cultures exposed to
HA of varying molecular weight for up to 21 days were
reported to have little or a negative effect on chondro-
genesis [38]. The experimental outcome was also inde-
pendent of the HA molecular weight used [38]. While
we are unaware of any previous reports describing the
ability of DS to influence chondrogenesis in adult MPC
cultures, heparin, dermatan sulfate, DS and heparan sul-
fate have been reported to stimulate nodule formation
and growth in 23/24-day chick mesenchymal MMS [39].
In another report using the same experimental culture
system, however, heparin and HA were found to inhibit
chondrogenesis [40].
Heparan sulfate PGs have been shown by several
groups to play a significant role in the control and dif-
ferentiation of MSCs. Indeed, heparan sulfate PGs have
been nominated to be the master regulators of MSC
Figure 9 Effects of pentosan polysulfate on human mesenchymal precursor stem cell differentiation: adipocyte formation. Bar graph
showing the concentration effects of pentosan polysulfate (PPS) on human mesenchymal precursor stem cell (MPC) adipogenic differentiation
when cultured for 28 days in an adipogenic inductive medium. Primary MPCs were cultured in nonadipogenic growth media (media control) or
under adipogenic conditions in the presence of PPS at the indicated concentrations. n = 3 for each PPS concentration studied. On day 28: (a)
levels of lipid determined relative to the total amount of DNA per well, and (b) phase-contrast photomicrography of Oil Red O-labelled
adipocytes (× 20). Data expressed as mean ± standard error of the mean. A statistically significant increase (P < 0.01) in adipocyte number was
observed at PPS concentrations > 1.0 μg/ml. *P < 0.01.
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niche as well as during tissue morphogenesis, neovascu-
larisation and wound repair [41]. Many of the heparan
sulfate PGs are present on cell surfaces as receptors
where they bind growth factors and orchestrate their
delivery and signal transduction to the cell nucleus [41].
These processes have been most extensively studied
using the fibroblast growth factors [41]. BMPs are well
documented as mediators of MSC differentiation [14,41]
but were not monitored in the present studies. However,
expression of Noggin, an antagonist of BMPs [42,43],
was significantly downregulated by PPS over the con-
centration range of 1 to 20 μg/ml. The effects of PPS on
TGF-b protein levels or expression were not examined
in this study but together with other important intracel-
lular signalling proteins are presently under
investigation.
PPS, heparin and heparan sulfate share common
structural features in that they all contain sulfate ester
group substituents in multiple ring positions of linear
polysaccharides. In PPS, the sulfate esters are symmetri-
cally located in the two and three positions of every
pentose ring. Heparin and heparan sulfate also contain a
sulfate ester group in the two position but the other sul-
fate is located on the amino group of the same glucosa-
mine ring. Unlike PPS, heparin and heparan sulfate are
heterogeneous molecules and can have additional sulfate
substitution in the iduronic acid ring as well as a num-
ber of other structural variations. Nevertheless, the 2/3
sulfate spatial pattern, which is common to all these sul-
fated polysaccharides, has been used to rationalise their
cross-reactivity with certain monoclonal antibodies [18],
their inhibitory activity against granulocyte elastase and
insulin-like growth factor binding protein (IGFBP)-5
proteolysis and certain serine proteases of the comple-
ment, haemostatic and fibrinogenic systems
[18,19,44,45]. It was therefore surprising to find in the
present studies that neither heparin nor DS promoted
MPC chondrogenesis, at least as assessed by the bio-
synthesis of PGs, indicating that the presence of the
highly negatively charged sulfate groups in the two and
three positions of polysaccharide chains were not critical
structural determinants of chondrogenic differentiation
by MPCs.
In the present real-time PCR experiments relative to
b-actin, collagen type I was the most strongly expressed
gene, followed by IGFBP-3. PPS at 1.0 and 10 μg/ml sig-
nificantly increased MPC expression of IGFBP-3; how-
ever, IGFBP-5 was only weakly expressed and marginally
upregulated by PPS (data not shown). IGFBP-3 has a
strong affinity for IGF-1 and, like IGFBP-5, can modu-
late its bioavailability and receptor binding - but in addi-
tion IGFBP-3 exhibits IGF-1-independent effects on
MSCs [4,46]. These direct effects of IGFBP-3 on MSCs
include suppression of proliferation, chondrogenesis,
adipogenesis and promotion of apoptosis [4,46].
Both IGFBP-3 and IGFBP-5 are degraded by the disin-
tegrin metalloprotease, ADAM-12 (meltrin-a) [47,48],
which therefore has the potential to influence the phy-
siological activities of these binding proteins. Impor-
tantly, ADAM12 has been reported be highly expressed
by the chondrocytes of osteoarthritis cartilage [49], a
sizable proportion of which may be MPCs [50]. More-
over, the extent of expression of ADAM12 by chondro-
cytes correlated with pathological markers of disease
progression such as cell cloning and proliferation [49].
Heparin and heparan sulfate have recently been
shown to bind to ADAM-12s and inhibit its proteolytic
activity [51]. In contrast, PPS enhanced ADAM-12s
degradation of IGFBP-3 [51]. This finding coupled with
our observations that PPS promoted MPC proliferation,
chondrogenesis, adipogenic differentiation while
decreasing osteogenesis, and apoptosis leads us to sug-
gest that some of these events could be mediated by the
increased proteolysis of IGFBP-3 by ADAM-12 due to
its interaction with PPS. Furthermore, enhanced proteo-
lysis of IGFBP-3 by ADAM12 would increase the bioa-
vailability of IGF-1, thereby also supporting MPC
proliferation and chondrogenic differentiation. On the
other hand, it has also been shown that the apoptosis-
potentiating and anti-proliferative activity of IGFBP-3
on MSCs may be antagonised through a TGF-b-depen-
dent ERK pathway [52], suggesting that the proliferative,
chondrogenic and anti-apoptotic effects of PPS on
MPCs could be mediated by their increased production
of TGF-b.
While additional investigations will be required to
clarify the mechanism of action of PPS on MPCs in
more detail, the outcomes of the present studies have
confirmed our working hypothesis that this drug could
be used in place of TGF-b or other related growth fac-
tors to induce chondrogenic differentiation of these
multipotent cells.
Conclusions
To our knowledge this is the first study to demonstrate
that the anti-osteoarthritis drug PPS possesses the ability
to promote MPC proliferation and chondrogenic differ-
entiation while suppressing osteogenic expression and
bone formation. Although additional studies are still
required to establish that these observed effects are also
mediated in vivo, in principal the combination of PPS
with MPCs alone or when integrated into a bioscaffold
could offer new therapeutic opportunities for the repair
and reconstitution of injured and degenerate cartilagi-
nous tissues of the musculoskeletal system.
Ghosh et al. Arthritis Research & Therapy 2010, 12:R28
http://arthritis-research.com/content/12/1/R28
Page 15 of 17Abbreviations
ADAM: a disintegrin and metalloprotease (adamlysin); ADAMTS: adamalysin
with thrombospondin motifs; BMP: bone morphogenetic protein; DS:
dextran polysulfate; DMEM: Dulbecco’s modified Eagle’s medium; ELISA:
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